CD112抗体及用途

What is AI technical title?
AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
By developing CD112 antibodies that can bind to CD112 and block its receptor binding, the applicability of existing immune checkpoint therapies has been addressed, achieving an anti-cancer promoting effect on immune cells.

CN116813771BActive Publication Date: 2026-07-17HEFEI TG IMMUNOPHARMA CO LTD

View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office: CN · China
Patent Type: Patents(China)
Current Assignee / Owner: HEFEI TG IMMUNOPHARMA CO LTD
Filing Date: 2023-05-09
Publication Date: 2026-07-17

Smart Images

Figure CN116813771B_ABST

Patent Text Reader

Abstract

本发明提出一种抗体或其抗原结合片段及其应用。其中，所述抗体或其抗原结合片段包括：轻链可变区CDR和重链可变区CDR；其中，重链可变区CDR1序列如GFTFSSYX1所示，重链可变区CDR2序列如INSQGGST所示，重链可变区CDR3序列如ARSDYDWAWX2AY所示，X1为Y或M，X2为F或Y；轻链可变区CDR1序列如QSLLYSSNQKNY所示；轻链可变区CDR2序列如WAX3所示，轻链可变区CDR3序列如QQYYRYPPT所示，X3为S或N。所述抗体或其抗原结合片段能够与人及猴CD112结合，阻断CD112与其受体CD112R、CD226、TIGIT的结合，能够促进免疫细胞抗癌功能。

Need to check novelty before this filing date? Find Prior Art